This report on treatment development for Duchenne muscular dystrophy contains news about fighting fibrosis (scarring), treating DMD-related heart disease, exon skipping and the corticosteroid deflazacort
posted on February 2, 2015 - 12:04pm
Development of treatments for Duchenne muscular dystrophy (DMD) continues to advance. Many of the new investigational drugs are potentially applicable to all DMD patients, while a few target those with specific mutations in the dystrophin gene.
A phase 2-3 clinical trial is testing whether an existing heart drug, eplerenone, can stop or slow heart damage in Duchenne muscular dystrophy
posted on June 29, 2012 - 6:00am
Eplerenone, a drug commonly used to prevent scarring after a heart attack, is being tested in a phase 2-3 clinical trial to determine whether it can stop or slow heart damage in people with Duchenne muscular dystrophy (DMD).
Eplerenone blocks scarring that over time can turn heart muscle into nonfunctioning fatty tissue.